
    
      To compare progression free survival (PFS) of the S-1 combined with docetaxel followed by
      maintenance treatment with S-1 and capecitabine combined with docetaxel followed by
      maintenance therapy with capecitabine in patients with advanced breast cancer first-line
      treatment.
    
  